脑性肾上腺脑白质营养不良基因治疗后血液系统肿瘤
该研究对两项已完成2-3期研究(ALD-102和ALD-104)及一项正在进行的随访研究(LTF-304)中接受eli-cel治疗的患者进行整合位点分析、遗传学、流式细胞术和形态学研究。67例接受eli-cel的患者中7例发生血液系统肿瘤,与克隆性载体插入 oncogenes 及体细胞遗传缺陷获得相关。
要点
- 67例接受eli-cel治疗的患者中7例发生血液系统肿瘤:ALD-102研究32例中1例,ALD-104研究35例中6例。
- 6例可获取数据的患者中,优势克隆携带慢病毒载体多 locus 插入,包括MECOM-EVI1(5例)或PRDM16(1例)。
- 7例中6例存在体细胞突变(KRAS、NRAS、WT1、CDKN2A或CDKN2B、RUNX1),1例存在单体7。
核心结论
- 接受eli-cel治疗的患者亚组中发生血液系统肿瘤,病例与癌基因内克隆性载体插入及获得体细胞遗传缺陷的克隆演化相关。
研究设计与样本
- 对两项已完成2-3期研究(ALD-102和ALD-104)及一项正在进行的随访研究(LTF-304)中接受eli-cel治疗的患者,进行整合位点分析、遗传学研究、流式细胞术和形态学研究。
主要发现
- 67例接受eli-cel的患者中7例发生血液系统肿瘤(ALD-102研究32例中1例,ALD-104研究35例中6例)。
- 血液系统肿瘤包括:2例伴单系发育异常的骨髓增生异常综合征(MDS)分别在14和26个月发生;3例伴原始细胞增多的MDS分别在28、42和92个月发生;1例MDS在36个月发生;1例急性髓系白血病(AML)在57个月发生。
- 6例可获取数据的患者中,优势克隆携带慢病毒载体多 locus 插入,包括MECOM-EVI1(5例)或PRDM16(1例)。
- 7例中6例存在体细胞突变(KRAS、NRAS、WT1、CDKN2A或CDKN2B、RUNX1),7例中1例存在单体7。
- 5例伴原始细胞增多的MDS或伴单系发育异常的MDS患者接受异基因造血干细胞移植(HSCT),其中4例无MDS复发且脑性肾上腺脑白质营养不良症状无复发,1例在HSCT后20个月(接受eli-cel后49个月)死于推测的移植物抗宿主病;AML患者在HSCT后存活且供者嵌合完全;最近一例MDS患者存活并等待HSCT。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gene therapy with elivaldogene autotemcel (eli-cel) consisting of autologous CD34+ cells transduced with lentiviral vector containing ABCD1 complementary DNA (Lenti-D) has shown efficacy in clinical studies for the treatment of cerebral adrenoleukodystrophy. However, the risk of oncogenesis with eli-cel is unclear. METHODS: We performed integration-site analysis, genetic studies, flow cytometry, and morphologic studies in peripheral-blood and bone marrow samples from patients who received eli-cel therapy in two completed phase 2-3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304) involving the patients in both ALD-102 and ALD-104. RESULTS: Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel (1 of 32 patients in the ALD-102 study and 6 of 35 patients in the ALD-104 study): myelodysplastic syndrome (MDS) with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 patients at 28, 42, and 92 months; MDS in 1 patient at 36 months; and acute myeloid leukemia (AML) in 1 patient at 57 months. In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including at either MECOM-EVI1 (MDS and EVI1 complex protein EVI1 [ecotropic virus integration site 1], in 5 patients) or PRDM16 (positive regulatory domain zinc finger protein 16, in 1 patient). Several patients had cytopenias, and most had vector insertions in multiple genes within the same clone; 6 of the 7 patients also had somatic mutations (KRAS, NRAS, WT1, CDKN2A or CDKN2B, or RUNX1), and 1 of the 7 patients had monosomy 7. Of the 5 patients with MDS with excess blasts or MDS with unilineage dysplasia who underwent allogeneic hematopoietic stem-cell transplantation (HSCT), 4 patients remain free of MDS without recurrence of symptoms of cerebral adrenoleukodystrophy, and 1 patient died from presumed graft-versus-host disease 20 months after HSCT (49 months after receiving eli-cel). The patient with AML is alive and had full donor chimerism after HSCT; the patient with the most recent case of MDS is alive and awaiting HSCT. CONCLUSIONS: Hematologic cancer developed in a subgroup of patients who were treated with eli-cel; the cases are associated with clonal vector insertions within oncogenes and clonal evolution with acquisition of somatic genetic defects. (Funded by Bluebird Bio; ALD-102, ALD-104, and LTF-304 ClinicalTrials.gov numbers, NCT01896102, NCT03852498, and NCT02698579, respectively.).
引用
- Duncan CN, Bledsoe JR, Grzywacz B, et al. Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2024. PMID: 39383458. doi:10.1056/NEJMoa2405541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。